Gujarat Themis Biosyn seeks shareholder approval via postal ballot to increase borrowing limits to ₹3,500 crore for business expansion and acquisitions.
The company also seeks approval to provide loans/guarantees/investments up to ₹3,500 crore beyond Section 186 limits for strategic flexibility.
Remote e-voting period runs from May 6 to June 4, 2026, with results to be declared by June 8, 2026.
The fund raise is partly intended for acquiring Sanofi's anti-TB and anti-infective brands portfolio subject to regulatory approvals.